AT&TSample data
Pilot & Enterprise Expansion · Enterprise Expansion

Enterprise Expansion Plan

The phased scaling plan from pilot to enterprise-wide rollout, with population waves, scaling criteria, and financial projections.

Sample dataModeled
Expansion waves
4
pilot → enterprise-wide
Observed
Total enrolled (all waves)
21,334
across 4 waves
Modeled
Scaling criteria met
2/8
gates for expansion
Observed
Enterprise net value (annual)
$68.0M
Wave 4 at full scale
Modeled

Expansion waves

Observed
1
Wave 1 (Pilot)
Distribution Center — Southeast
Year 1
In progress
Eligible / Enrolled: 270,000 covered / 81,000 eligible / 5,400 enrolledCare team capacity: 2,600
Capacity utilization
77%
2
Wave 2
Southeast region (all DCs)
Year 3
Planned
Eligible / Enrolled: 270,000 covered / 81,000 eligible / 10,200 enrolledCare team capacity: 4,978
Capacity utilization
76%
3
Wave 3
Southeast + Midwest regions
Year 5
Planned
Eligible / Enrolled: 270,000 covered / 81,000 eligible / 15,000 enrolledCare team capacity: 7,356
Capacity utilization
76%
4
Wave 4 (Enterprise)
All regions (enterprise-wide)
Year 10
Planned
Eligible / Enrolled: 270,000 covered / 81,000 eligible / 27,000 enrolledCare team capacity: 13,000
Capacity utilization
77%

Scaling criteria

Observed
Gate 4 passed — positive net ROI validatedMetWave 2
Care team capacity confirmed for 3,500 membersMetWave 2
HRIS integration scaled for multi-regionPendingWave 3
Pharmacy network capacity for 8,000 membersPendingWave 3
Data platform validated at 15,000+ recordsPendingWave 3
Governance and compliance framework enterprise-readyPendingWave 4
Budget approved for enterprise rolloutPendingWave 4
Care team capacity for 45,000 membersPendingWave 4

Expansion financial projection (annual, $M)

Modeled
WaveEnrolledFeesCost AvoidanceProductivityNet Value
Wave 1 (Pilot)2,000$10.8M$3.4M$11.4M$4.0M
Wave 23,778$20.4M$6.5M$21.5M$7.6M
Wave 35,556$30.0M$9.5M$31.7M$11.2M
Wave 4 (Enterprise)10,000$54.0M$17.1M$57.0M$20.1M

Net value = cost avoidance + productivity value − program fees. All figures are illustrative modeled projections based on pilot assumptions and are not validated financial results.

Enterprise expansion vision

Over 48 months, the program scales from a 1,000-member pilot in the Southeast to a 40,000-member enterprise-wide initiative reaching all eligible AT&T employees. The phased approach validates clinical efficacy, financial impact, and operational feasibility at each wave before expanding. Wave 4 (enterprise-wide) projects an annual net value of $68M, combining $44M in cost avoidance and $72M in productivity value against $48M in program fees.

Phased validationCapacity-gated scalingGate-based decisions

Employee Privacy Protected by Design

Employer reporting is designed to present aggregate workforce and health-program insights without exposing individual clinical records. Small-group reporting restrictions help reduce the risk of employee identification.

Sample dataPrivacy-restricted reporting

Aggregated information is not described as HIPAA-de-identified unless applicable de-identification requirements have been satisfied and verified.

Sample Data — Demonstration Only. Fictional data, not actual patient records or validated outcomes.